simoctocog alfa at a glance
Medicine class
Recombinant human coagulation factor VIII
Licensed role
Treatment and prevention of bleeding in congenital haemophilia A
How it is given
Injection into a vein after reconstitution
Who can use it
Licensed for all age groups under specialist haemophilia care
What is simoctocog alfa used for?
Licensed uses are:
Treatment of bleeding in haemophilia A caused by congenital factor VIII deficiency.
Prevention of bleeding in haemophilia A, including around planned surgery when directed by the specialist team.
Use in adults, adolescents and children of all ages.
How does simoctocog alfa work?
It temporarily restores factor VIII activity. After binding to von Willebrand factor, activated factor VIII supports activation of factor X, leading to thrombin and fibrin formation so a stable blood clot can develop.
simoctocog alfa preparations and strengths
Injection
Route: Parenteral
Strengths: 250 units, 500 units, 1000 units, 1500 units, 2000 units
How to take simoctocog alfa
Use only as taught by the haemophilia team. The powder is reconstituted with the supplied water for injections and equipment, then injected into a vein.
Let unopened vials and solvent reach room temperature without an external heat source.
Gently swirl the vial; do not shake it.
Use only a clear, colourless solution without visible particles or deposits.
Use the supplied injection equipment and do not mix the solution with other medicines.
Record the product name and batch number after each administration.
simoctocog alfa side effects
Common or expected effects
- Fever
- Allergic-type reactions, including rash or hives
Get urgent medical advice
- Severe allergic reaction or anaphylaxis, including facial or tongue swelling, wheezing, chest tightness, low blood pressure or collapse
- Development of factor VIII inhibitors, suggested by persistent or increasingly frequent bleeding or an inadequate factor VIII response
- Potential complications of a central venous access device, including infection or catheter-related thrombosis
simoctocog alfa in pregnancy
Product-specific pregnancy experience is limited, so it should be used only when clearly indicated. Pregnancy in someone with haemophilia or low factor VIII requires coordinated planning between haemophilia, obstetric and anaesthetic specialists.
simoctocog alfa while breastfeeding
Product-specific breastfeeding experience is limited, and use should be clearly indicated and discussed with the specialist team. Factor concentrate is considered compatible with breastfeeding in specialist patient information, but individual circumstances need review.
simoctocog alfa interactions
Formal interaction studies have not been performed. A medicine review remains important because some treatments independently increase bleeding risk.
Aspirin and non-steroidal anti-inflammatory medicines
These can increase bleeding or bruising in people with bleeding disorders; check with the haemophilia team before use.
Anticoagulants such as warfarin, heparin, apixaban or rivaroxaban
These increase bleeding risk and require specialist awareness and planning.
Other medicines mixed in the same syringe or infusion equipment
Compatibility has not been established; mixing or unsuitable equipment may reduce delivery of factor VIII.
Common questions about simoctocog alfa
Answers are fully visible for fast scanning and source review.
What condition does simoctocog alfa treat?
It is licensed to treat and prevent bleeding in congenital haemophilia A, where factor VIII is deficient.
How is it administered?
It is reconstituted and injected into a vein. Patients or carers may administer it at home only after appropriate training.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.